Results 231 to 240 of about 283,064 (357)

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Proton Beam Therapy Versus Photon Radiotherapy for Pediatric Neuroblastoma: A Systematic Review and Meta-Analysis (TRP-2025 Neuroblastoma). [PDF]

Cancer Med
Nitta H, Mizumoto M, Maruo K, Oshiro Y, Li Y, Inaba M, Saito T, Hosaka S, Iizumi T, Fukushima H, Suzuki R, Shimizu S, Nakai K, Sakurai H.   +13 more
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Survival outcomes and relapse patterns in high-risk metastatic neuroblastoma treated with radiotherapy-only consolidation in a resource-limited setting: a retrospective study from a lower-middle-income country. [PDF]

Front Oncol
Alabedi HH, Abdulrahman NM, Al-Rudayni AH.   +2 more
europepmc   +1 more source

Immunohistochemistry as a tool for identifying EGFR amplification in CNS tumors

Brain Pathology, EarlyView.
EGFR gene amplification constitutes a diagnostic hallmark for glioblastoma, IDH‐wildtype (GB, IDH‐WT). Herein, we demonstrated that EGFR IHC is a highly specific and sensitive biomarker for identifying EGFR amplification and should be part of the neuropathologist's routine panel of antibodies.
Arnault Tauziède‐Espariat, Mary Bah, Farah Sassi, Noémie Pucelle, Charlotte Berthaud, Marion Mandoula, Zeina Dababou, Noah Carnes, Leïla Brissez, Lauren Hasty, Euphrasie Servant, Alice Métais, Pascale Varlet   +12 more
wiley   +1 more source

Therapy-related acute myeloid leukemia following successful treatment of high-risk neuroblastoma in a pediatric patient: a case report and insights into late complications. [PDF]

Front Oncol
He SJ, Gao J, Qiao LN, He GQ, Guo X, Jing XY.   +5 more
europepmc   +1 more source

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease

Brain Pathology, EarlyView.
SIDT2‐immunoreactive inclusions are observed in the striatum, cerebral cortex, and hypothalamus in HD cases with different Vonsattel grades, and the frequency of SIDT2‐immunoreactive inclusions is associated with longer CAG repeats in the huntingtin gene.
Sanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, Rachel Y. Cheong, Barbara Baldo, Paul Günther Scheunemann, Marie‐Louisa Schoebel, Linda Holmquist Mengelbier, Elisabet Englund, Catriona McLean, Carsten Saft, Deniz Kirik, Maria Björkqvist, Glenda Halliday, Elisabeth Petrasch‐Parwez, Huu Phuc Nguyen, Jonasz Jeremiasz Weber, Åsa Petersén   +17 more
wiley   +1 more source

The roles and pathways of Hsa_circ_0000285 in cancer: a potential target for cancer therapy. [PDF]

Cell Div
Lv Y, Li D, Zhang QX, Zeng T, Luo XY, Guo Q, Ren QY.   +6 more
europepmc   +1 more source

MOESM5 of Systematic computational identification of prognostic cytogenetic markers in neuroblastoma

, 2019
Chao Qin, Xiaoyan He, Yanding Zhao, Chun-Yip Tong, Kenneth Zhu, Yongqi Sun, Chao Cheng   +6 more
openalex   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source